obesity-995x60.png
FEATURED ARTICLES
Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors
CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.
-
![Online testing, questionaire, voting-GettyImages-873499310]( "What Pistoia Alliance's AI Poll Reveals About Industry Readiness And Regulatory Confidence")
What Pistoia Alliance's AI Poll Reveals About Industry Readiness And Regulatory ConfidencePistoia Alliance President Becky Upton, Ph.D., reviews findings from a poll about AI use in clinical research conducted at Clinical Trials Technology Congress (CTTC) that revealed barriers to adoption, early ROI, emerging use cases, and the role of patient-generated data.
-
![Busy surgery waiting room-GettyImages-1208597148]( "Early Patient Education And Community Outreach Are Advancing Representation In Clinical Trials")
Early Patient Education And Community Outreach Are Advancing Representation In Clinical TrialsMerck Executive Director, Clinical Trial Patient Representation, Adrelia Allen argues that patient awareness, access, early information, and trust shape are the pillars of patient representation in clinical trials.
-
![clinical-trial-design-GettyImages-2246070389]( "Managing Medical Coding Dictionary Updates In Clinical Trials")
Managing Medical Coding Dictionary Updates In Clinical TrialsDictionary updates can impact data consistency, safety monitoring, and reporting. Learn key considerations for managing coding version changes while maintaining data integrity.
SERVICES AND PRODUCTS
Proof-of-concept provides a critical bridge between Phase 1 and Phase 2 trials, making an experienced CRO partner vital to achieving optimal outcomes for early-phase clinical research.
Cardinal Symptom Monitoring for Parkinson's and Huntington's Disease Trials
Continuous, objective tracking of cardinal symptoms in chronic diseases can support a better understanding of disease progression and treatment response.
Rapidly reduced timelines and waste, and the prevention of costly product shortages
In a world that is constantly changing, the development of innovative personalised medicine is helping more of us to live healthier lives for longer. These leaps forward in drug development create new hope for patients.
Yet operating high-value, time-sensitive supply chains naturally brings additional challenge and risk. Challenge and risk that require a step change in production approach to effectively balance patient-centricity with commercial viability.
Almac Trial Coordinator™ is a unified eClinical orchestration solution designed to simplify the execution of complex clinical trials. It brings together core trial functions including Interactive Response Technology (IRT), electronic Clinical Outcome Assessments (eCOA), eConsent, visit and participant management, and clinical supply oversight within a single, cohesive ecosystem.
Rather than operating as a collection of disconnected point solutions, Almac Trial Coordinator™ is designed to coordinate workflows, data, and users across the clinical trial lifecycle. The result is a more efficient, transparent, and site-friendly way to run global studies.
Boost patient engagement. Simplify and reduce site workload. Enable real-time, local currency payments through the patient’s preferred method.
Trial Enablement Solutions
Digital health technologies have the potential to transform clinical trials, yet without careful planning and operational support, their implementation can create complexity, increase site burden, and jeopardize data quality.
Backed by over 20 years of experience across nearly 300 industry-sponsored trials, Ametris’ Digital Health Operations team delivers end-to-end trial enablement services to ensure seamless technology deployment, reduce site burden, and capture reliable, high-quality data.